Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total		Class A Common Stock	Common stock	Common stock Class A Common Stock	Common stock Class B Common Stock	Additional Pain-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Stockholders' Equity, beginning balance (in shares) at Jan. 31, 2024					114,670,000	42,887,000
Stockholders' Equity, beginning balance at Jan. 31, 2024	$ 606,392				$ 0	$ 0	$ 1,718,661	$ (1,161,288)	$ 2,398	$ 46,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					23,110,000	(23,110,000)
Issuance of common stock related to vested exercised stock options (in shares)						1,778,000
Issuance of common stock related to vested exercised stock options	17,904						17,904
Issuance of common stock under employee stock purchase plan (in shares)					252,000
Issuance of common stock under employee stock purchase plan	7,932						7,932
Issuance of common stock related to RSUs and PSUs vested (in shares)					2,323,000
Charitable donation of common stock (in shares)			173,181		173,000
Charitable donation of common stock	8,871		$ 8,900				8,871
Vesting of early exercised stock options	267						267
Stock-based compensation expense	139,263						138,427			836
Change in noncontrolling interest ownership							(409)			409
Other comprehensive loss	(7,767)								(7,496)	(271)
Net Income (loss)	(15,434)							(13,218)		(2,216)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2024					140,528,000	21,555,000
Stockholders' Equity, ending balance at Oct. 31, 2024	757,428				$ 0	$ 0	1,891,653	(1,174,506)	(5,098)	45,379
Stockholders' Equity, beginning balance (in shares) at Jul. 31, 2024					136,462,000	23,963,000
Stockholders' Equity, beginning balance at Jul. 31, 2024	675,826				$ 0	$ 0	1,833,786	(1,203,609)	623	45,026
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					3,255,000	(3,255,000)
Issuance of common stock related to vested exercised stock options (in shares)						847,000
Issuance of common stock related to vested exercised stock options	7,830						7,830
Issuance of common stock related to RSUs and PSUs vested (in shares)					758,000
Charitable donation of common stock (in shares)			52,940		53,000
Charitable donation of common stock	2,957		$ 3,000				2,957
Vesting of early exercised stock options	78						78
Stock-based compensation expense	48,042						47,002			1,040
Other comprehensive loss	(5,110)								(5,721)	611
Net Income (loss)	27,805							29,103		(1,298)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2024					140,528,000	21,555,000
Stockholders' Equity, ending balance at Oct. 31, 2024	757,428				$ 0	$ 0	1,891,653	(1,174,506)	(5,098)	45,379
Stockholders' Equity, beginning balance (in shares) at Jan. 31, 2025					144,444,000	19,469,000
Stockholders' Equity, beginning balance at Jan. 31, 2025	$ 821,306	[1]			$ 0	$ 0	1,952,031	(1,167,614)	(8,508)	45,397
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					2,114,000	(2,122,000)
Issuance of common stock related to vested exercised stock options (in shares)	1,235,000					1,235,000
Issuance of common stock related to vested exercised stock options	$ 15,471						15,471
Issuance of common stock under employee stock purchase plan (in shares)					256,000
Issuance of common stock under employee stock purchase plan	8,404						8,404
Repurchases, net of early exercised stock options (in shares)						(1,000)
Issuance of common stock related to RSUs and PSUs vested (in shares)					2,797,000
Common stock withheld related to net share settlement of equity awards (in shares)				(11,000)
Common stock withheld related to net share settlement of equity awards	(529)						(529)
Charitable donation of common stock (in shares)			122,667		123,000
Charitable donation of common stock	5,496		$ 5,500				5,496
Vesting of early exercised stock options	56						56
Stock-based compensation expense	162,160						160,711			1,449
Change in noncontrolling interest ownership							92			(92)
Other comprehensive loss	10,684								10,464	220
Net Income (loss)	(55,051)							(53,359)		(1,692)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2025					149,723,000	18,581,000
Stockholders' Equity, ending balance at Oct. 31, 2025	967,997	[1]			$ 0	$ 0	2,141,732	(1,220,973)	1,956	45,282
Stockholders' Equity, beginning balance (in shares) at Jul. 31, 2025					147,834,000	18,876,000
Stockholders' Equity, beginning balance at Jul. 31, 2025	911,582				$ 0	$ 0	2,080,759	(1,212,697)	(1,511)	45,031
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of stock (in shares)					880,000	(888,000)
Issuance of common stock related to vested exercised stock options (in shares)						593,000
Issuance of common stock related to vested exercised stock options	8,182						8,182
Issuance of common stock related to RSUs and PSUs vested (in shares)					979,000
Common stock withheld related to net share settlement of equity awards (in shares)				(11,000)
Common stock withheld related to net share settlement of equity awards	(529)						(529)
Charitable donation of common stock (in shares)			40,889	41,000
Charitable donation of common stock	1,970		$ 2,000				1,970
Vesting of early exercised stock options	3						3
Stock-based compensation expense	52,049						51,353			696
Change in noncontrolling interest ownership							(6)			6
Other comprehensive loss	3,537								3,467	70
Net Income (loss)	(8,797)							(8,276)		(521)
Stockholders' Equity, ending balance (in shares) at Oct. 31, 2025					149,723,000	18,581,000
Stockholders' Equity, ending balance at Oct. 31, 2025	$ 967,997	[1]			$ 0	$ 0	$ 2,141,732	$ (1,220,973)	$ 1,956	$ 45,282

[1] (1) As of October 31, 2025 and January 31, 2025, the condensed consolidated balance sheet includes assets of the consolidated variable interest entity, GitLab Information Technology (Hubei) Co., LTD (“JiHu”), of $41.6 million and $46.5 million, respectively, and liabilities of $7.2 million and $10.3 million respectively. The assets of JiHu can be used only to settle obligations of JiHu and creditors of JiHu do not have recourse against the general credit of the Company. Refer to “Note 10. Joint Venture” for further discussion.